Paraskevi V Voulgari

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4881850/publications.pdf

Version: 2024-02-01

172 papers

3,543 citations

30 h-index 54 g-index

177 all docs

177 docs citations

times ranked

177

4395 citing authors

#	Article	IF	CITATIONS
1	Incidence and Prevalence of Rheumatoid Arthritis, Based on the 1987 American College of Rheumatology Criteria: A Systematic Review. Seminars in Arthritis and Rheumatism, 2006, 36, 182-188.	3.4	621
2	Demyelination and other neurological adverse events after anti-TNF therapy. Autoimmunity Reviews, 2014, 13, 54-58.	5.8	147
3	Early Treatment Reduces the Cardiovascular Risk Factors in Newly Diagnosed Rheumatoid Arthritis Patients. Seminars in Arthritis and Rheumatism, 2008, 38, 13-19.	3.4	97
4	Granuloma annulare induced by anti-tumour necrosis factor therapy. Annals of the Rheumatic Diseases, 2008, 67, 567-570.	0.9	97
5	Efficacy and safety of switching from infliximab to adalimumab: a comparative controlled study. Annals of the Rheumatic Diseases, 2006, 65, 257-260.	0.9	94
6	Esophageal Involvement in Scleroderma: Gastroesophageal Reflux, the Common Problem. Seminars in Arthritis and Rheumatism, 2006, 36, 173-181.	3.4	93
7	Gender and age differences in systemic lupus erythematosus. A study of 489 Greek patients with a review of the literature. Lupus, 2002, 11, 722-729.	1.6	87
8	Neurological adverse events in patients receiving anti-TNF therapy: a prospective imaging and electrophysiological study. Arthritis Research and Therapy, 2014, 16, R125.	3.5	87
9	Immune-mediated skin lesions in patients treated with anti-tumour necrosis factor alpha inhibitors. Scandinavian Journal of Rheumatology, 2009, 38, 328-331.	1.1	85
10	Does cigarette smoking influence disease expression, activity and severity in early rheumatoid arthritis patients?. Clinical and Experimental Rheumatology, 2005, 23, 861-6.	0.8	81
11	Comparative effectiveness and survival of infliximab, adalimumab, and etanercept for rheumatoid arthritis patients in the Hellenic Registry of Biologics: Low rates of remission and 5-year drug survival. Seminars in Arthritis and Rheumatism, 2014, 43, 447-457.	3.4	80
12	Epidemiology of ankylosing spondylitis in Northwest Greece, 1983-2002. British Journal of Rheumatology, 2004, 43, 615-618.	2.3	78
13	Epidemiology of adult rheumatoid arthritis in northwest Greece 1987-1995. Journal of Rheumatology, 1997, 24, 2129-33.	2.0	70
14	Infliximab therapy in patients with ankylosing spondylitis: an open label 12 month study. Annals of the Rheumatic Diseases, 2003, 62, 1218-1220.	0.9	67
15	Cardiovascular risk profile in patients with spondyloarthritis. Joint Bone Spine, 2014, 81, 57-63.	1.6	63
16	Laryngeal involvement in rheumatoid arthritis. Rheumatology International, 2005, 25, 321-325.	3.0	56
17	Infliximab therapy in established rheumatoid arthritis: An observational study. American Journal of Medicine, 2005, 118, 515-520.	1.5	53
18	Treatment strategies are more important than drugs in the management of rheumatoid arthritis. Clinical Rheumatology, 2020, 39, 1363-1368.	2.2	47

#	Article	IF	CITATIONS
19	Primary Sjögren's Syndrome of Early and Late Onset: Distinct Clinical Phenotypes and Lymphoma Development. Frontiers in Immunology, 2020, 11, 594096.	4.8	45
20	A prospective multicenter study assessing humoral immunogenicity and safety of the mRNA SARS-CoV-2 vaccines in Greek patients with systemic autoimmune and autoinflammatory rheumatic diseases. Journal of Autoimmunity, 2021, 125, 102743.	6.5	45
21	Radiological cervical spine involvement in patients with rheumatoid arthritis: a cross sectional study. Journal of Rheumatology, 2005, 32, 801-6.	2.0	45
22	Sustained Clinical Response in Psoriatic Arthritis Patients Treated with Anti-TNF Agents: A 5-year Open-Label Observational Cohort Study. Seminars in Arthritis and Rheumatism, 2011, 40, 398-406.	3.4	44
23	Comparative Analysis and Predictors of 10-year Tumor Necrosis Factor Inhibitors Drug Survival in Patients with Spondyloarthritis: First-year Response Predicts Longterm Drug Persistence. Journal of Rheumatology, 2018, 45, 785-794.	2.0	43
24	Prognostic Factors of Radiological Damage in Rheumatoid Arthritis: A 10-year Retrospective Study. Journal of Rheumatology, 2011, 38, 44-52.	2.0	39
25	The role of psychological distress and personality variables in the disablement process in rheumatoid arthritis. Scandinavian Journal of Rheumatology, 2009, 38, 419-430.	1.1	38
26	The lipid paradox in rheumatoid arthritis: the dark horse of the augmented cardiovascular risk. Rheumatology International, 2020, 40, 1181-1191.	3.0	38
27	Golimumab for Rheumatoid Arthritis. Journal of Clinical Medicine, 2019, 8, 387.	2.4	34
28	Coping with health-stressors and defence styles associated with health-related quality of life in patients with systemic lupus erythematosus. Lupus, 2011, 20, 893-903.	1.6	33
29	Unmet needs in the treatment of rheumatoid arthritis. An observational study and a real-life experience from a single university center. Seminars in Arthritis and Rheumatism, 2019, 48, 597-602.	3.4	33
30	Disease modifying antirheumatic drugs in early rheumatoid arthritis: a longterm observational study. Journal of Rheumatology, 2002, 29, 261-6.	2.0	32
31	Magnetic resonance imaging quantification of hand synovitis in patients with rheumatoid arthritis treated with adalimumab. Journal of Rheumatology, 2006, 33, 219-23.	2.0	32
32	Psychological distress and personality traits in early rheumatoid arthritis: a preliminary survey. Rheumatology International, 2006, 26, 828-836.	3.0	30
33	Rheumatological manifestations in inflammatory bowel disease. Annals of Gastroenterology, 2011, 24, 173-180.	0.6	30
34	Effects of 12 months of treatment with disease-modifying anti-rheumatic drugs on low and high density lipoprotein subclass distribution in patients with early rheumatoid arthritis: a pilot study. Scandinavian Journal of Rheumatology, 2013, 42, 169-175.	1.1	27
35	Sjögren's Syndrome: The Clinical Spectrum of Male Patients. Journal of Clinical Medicine, 2020, 9, 2620.	2.4	26
36	Maintained clinical response of infliximab treatment in ankylosing spondylitis: A 6-year long-term study. Joint Bone Spine, 2010, 77, 325-329.	1.6	24

#	Article	IF	CITATIONS
37	Cardiovascular risk factors in HIV infected individuals: Comparison with general adult control population in Greece. PLoS ONE, 2020, 15, e0230730.	2.5	24
38	A biomarker for lymphoma development in Sjogren's syndrome: Salivary gland focus score. Journal of Autoimmunity, 2021, 121, 102648.	6.5	24
39	Adalimumab for rheumatoid arthritis. Expert Opinion on Biological Therapy, 2006, 6, 1349-1360.	3.1	23
40	Induction of psoriatic skin lesions in a patient with rheumatoid arthritis treated with rituximab. Clinical and Experimental Rheumatology, 2009, 27, 996-8.	0.8	23
41	Impaired Antiatherogenic Functions of High-density Lipoprotein in Patients with Ankylosing Spondylitis. Journal of Rheumatology, 2015, 42, 1652-1660.	2.0	22
42	Eight-year survival study of first-line tumour necrosis factor \hat{l}_{\pm} inhibitors in rheumatoid arthritis: real-world data from a university centre registry. Rheumatology Advances in Practice, 2019, 3, rkz007.	0.7	21
43	High prevalence of cardiovascular risk factors in adults living in Greece: the EMENO National Health Examination Survey. BMC Public Health, 2020, 20, 1665.	2.9	21
44	Sustained Clinical Response and High Infliximab Survival in Psoriatic Arthritis Patients: A 3-year Long-Term Study. Seminars in Arthritis and Rheumatism, 2008, 37, 293-298.	3.4	20
45	Emerging drugs for rheumatoid arthritis. Expert Opinion on Emerging Drugs, 2008, 13, 175-196.	2.4	20
46	Rheumatoid Arthritis Treatment. A Back to the Drawing Board Project or High Expectations for Low Unmet Needs?. Journal of Clinical Medicine, 2019, 8, 1237.	2.4	19
47	Persistent clinical response of infliximab treatment, over a 4-year period in ankylosing spondylitis. Rheumatology International, 2007, 27, 935-939.	3.0	18
48	Effect of Hydroxychloroquine on the Lipid Profile of Patients with Sjögren Syndrome. Journal of Rheumatology, 2014, 41, 902-908.	2.0	18
49	Cytokine profile in drug-na \tilde{A}^- ve, first episode patients with psychosis. Journal of Psychosomatic Research, 2015, 79, 324-327.	2.6	18
50	Altered sequence of the <i>ETS1 </i> transcription factor may predispose to rheumatoid arthritis susceptibility. Scandinavian Journal of Rheumatology, 2013, 42, 11-14.	1.1	17
51	Conventional radiography of the hands and wrists in rheumatoid arthritis. What a rheumatologist should know and how to interpret the radiological findings. Rheumatology International, 2019, 39, 1331-1341.	3.0	17
52	Cyclosporine A in the treatment of early rheumatoid arthritis. A prospective, randomized 24-month study. Clinical and Experimental Rheumatology, 1998, 16, 695-701.	0.8	17
53	High 3-year golimumab survival in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: real world data from 328 patients. Clinical and Experimental Rheumatology, 2018, 36, 254-262.	0.8	17
54	Sirukumab: a promising therapy for rheumatoid arthritis. Expert Opinion on Biological Therapy, 2017, 17, 755-763.	3.1	16

#	Article	IF	Citations
55	Therapeutic Options and Cost-Effectiveness for Rheumatoid Arthritis Treatment. Current Rheumatology Reports, 2020, 22, 44.	4.7	15
56	Transfusion-related Acute Lung Injury During Intravenous Immunoglobulin Treatment. Journal of Rheumatology, 2010, 37, 190-191.	2.0	14
57	Adalimumab in the treatment of rheumatoid arthritis. Expert Opinion on Biological Therapy, 2012, 12, 1679-1686.	3.1	14
58	ABP 501 for the treatment of rheumatoid arthritis. Expert Opinion on Biological Therapy, 2018, 18, 317-322.	3.1	14
59	<p>Clinical evaluation of the safety, efficacy and tolerability of sarilumab in the treatment of moderate to severe rheumatoid arthritis</p> . Therapeutics and Clinical Risk Management, 2019, Volume 15, 1073-1079.	2.0	14
60	National Survey of Morbidity and Risk Factors (EMENO): Protocol for a Health Examination Survey Representative of the Adult Greek Population. JMIR Research Protocols, 2019, 8, e10997.	1.0	14
61	Fasting mimicking diets: A literature review of their impact on inflammatory arthritis. Mediterranean Journal of Rheumatology, 2019, 30, 201.	0.8	14
62	Anti-Rheumatic Drugs for the Fight Against the Novel Coronavirus Infection (SARSCoV-2): What is the Evidence?. Mediterranean Journal of Rheumatology, 2020, 31, 259.	0.8	14
63	Rheumatoid arthritis in patients with hemoglobinopathies. Rheumatology International, 2012, 32, 2889-2892.	3.0	13
64	Golimumab, the newest TNF- \hat{l}_{\pm} blocker, comes of age. Clinical and Experimental Rheumatology, 2015, 33, 570-7.	0.8	13
65	Granuloma annulare development in a patient with rheumatoid arthritis treated with tocilizumab: case-based review. Rheumatology International, 2019, 39, 353-357.	3.0	12
66	Treatment modalities and drug survival in a systemic sclerosis real-life patient cohort. Arthritis Research and Therapy, 2020, 22, 56.	3.5	12
67	Colchicine Against SARS-CoV-2 Infection: What is the Evidence?. Rheumatology and Therapy, 2022, 9, 379-389.	2.3	12
68	Golimumab: a new anti-TNF- \hat{l}_{\pm} agent for rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. Expert Review of Clinical Immunology, 2010, 6, 721-733.	3.0	11
69	Changes in the cytokine profile in first-episode, drug-naÃ-ve patients with psychosis after short-term antipsychotic treatment. Psychiatry Research, 2017, 256, 378-383.	3.3	11
70	Radiological Findings of the Cervical Spine in Rheumatoid Arthritis: What a Rheumatologist Should Know. Current Rheumatology Reports, 2020, 22, 19.	4.7	11
71	Certolizumab for rheumatoid arthritis. Clinical and Experimental Rheumatology, 2014, 32, 415-23.	0.8	11
72	Effect of very early treatment in rheumatoid arthritis on bone oedema and synovitis, using magnetic resonance imaging. Scandinavian Journal of Rheumatology, 2012, 41, 339-344.	1.1	10

#	Article	IF	CITATIONS
73	Successful treatment with rituximab of IgG4-related disease coexisting with adult-onset asthma and periocular xanthogranuloma. Rheumatology International, 2020, 40, 671-677.	3.0	10
74	Preclinical discovery and development of adalimumab for the treatment of rheumatoid arthritis. Expert Opinion on Drug Discovery, 2021, 16, 227-234.	5.0	10
75	Biologic Therapies and Autoimmune Phenomena. Mediterranean Journal of Rheumatology, 2021, 32, 96.	0.8	10
76	COVID-19 in patients with gout on colchicine. Rheumatology International, 2021, 41, 1503-1507.	3.0	10
77	Use of conventional synthetic and biologic disease-modifying anti-rheumatic drugs in patients with rheumatic diseases contracting COVID-19: a single-center experience. Rheumatology International, 2021, 41, 903-909.	3.0	9
78	Tuberculous pyomyositis in a rheumatoid arthritis patient treated with anakinra. Clinical and Experimental Rheumatology, 2015, 33, 734-6.	0.8	9
79	Janus kinase versus TNF inhibitors: where we stand today in rheumatoid arthritis. Expert Review of Clinical Immunology, 2022, 18, 485-493.	3.0	9
80	Sinus histocytosis with massive lymphadenopathy (Rosai–Dorfman disease) in a patient with primary Sjogren's syndrome. Scandinavian Journal of Rheumatology, 2004, 33, 119-122.	1.1	8
81	In transit Recurrence of Merkel Cell Carcinoma Associated with Polyarthritis Effectively Treated with Immunocryosurgery. Acta Dermato-Venereologica, 2014, 94, 739-740.	1.3	8
82	The impact of temporal artery biopsy for the diagnosis of giant cell arteritis in clinical practice in a tertiary university hospital. PLoS ONE, 2019, 14, e0210845.	2.5	8
83	Adalimumab-induced myasthenia gravis: case-based review. Rheumatology International, 2020, 40, 1891-1894.	3.0	8
84	Incidence, risk factors and validation of the RABBIT score for serious infections in a cohort of 1557 patients with rheumatoid arthritis. Rheumatology, 2021, 60, 2223-2230.	1.9	8
85	Cardiovascular Disease in Spondyloarthritides. Current Vascular Pharmacology, 2020, 18, 473-487.	1.7	8
86	Sj $\tilde{A}\P$ gren Syndrome Associated with Inflammatory Muscle Diseases. Mediterranean Journal of Rheumatology, 2018, 29, 92-96.	0.8	8
87	Prevalence, awareness, treatment and control of hypertension in Greece: EMENO national epidemiological study. Journal of Hypertension, 2021, 39, 1034-1039.	0.5	8
88	Seronegative Erosive Arthritis Following SARS-CoV-2 Infection. Rheumatology and Therapy, 2022, 9, 295-301.	2.3	8
89	Combined seronegativity in Sjögren's syndrome. Clinical and Experimental Rheumatology, 2021, 39, 80-84.	0.8	8
90	A single pulmonary rheumatoid nodule masquerading as malignancy. Clinical Rheumatology, 2005, 24, 556-559.	2.2	7

#	Article	IF	Citations
91	Recent advances in the opioid mu receptor based pharmacotherapy for rheumatoid arthritis. Expert Opinion on Pharmacotherapy, 2020, 21, 2153-2160.	1.8	7
92	The changing incidence of rheumatoid arthritis over time in north-west Greece: data from a referral centre. Scandinavian Journal of Rheumatology, 2023, 52, 327-334.	1.1	7
93	Antierythropoietin antibodies in thalassemia patients. Annals of Hematology, 2004, 83, 22-27.	1.8	6
94	Prevalence of diabetes and pre-diabetes in Greece. Results of the First National Survey of Morbidity and Risk Factors (EMENO) study. Diabetes Research and Clinical Practice, 2021, 172, 108646.	2.8	6
95	Cutaneous Autoimmune Phenomena of the Anti-TNFa Biosimilars. Casebased Review. Current Rheumatology Reviews, 2021, 17, 267-270.	0.8	6
96	Prevalence of tobacco smoking and association with other unhealthy lifestyle risk factors in the general population of Greece: Results from the EMENO study. Tobacco Prevention and Cessation, 2021, 7, 1-13.	0.4	6
97	Neuroinflammatory events after anti-TNFα therapy. Annals of the Rheumatic Diseases, 2022, 81, e73-e73.	0.9	6
98	Counting Costs under Severe Financial Constraints: A Cost-of-Illness Analysis of Spondyloarthropathies in a Tertiary Hospital in Greece. Journal of Rheumatology, 2015, 42, 963-967.	2.0	5
99	Liver perivascular epithelioid cell tumor in a patient with systemic lupus erythematosus. International Journal of Surgery Case Reports, 2018, 53, 193-195.	0.6	5
100	TNF-induced Lupus. A Case-Based Review. Current Rheumatology Reviews, 2022, 18, 72-82.	0.8	5
101	Long COVID from rheumatology perspective: a simple mimicker or promoter of autoimmunity?. Clinical Rheumatology, 2022, 41, 957-958.	2.2	5
102	Gingival hyperplasia associated with cyclosporin A. Journal of Rheumatology, 2002, 29, 2466.	2.0	5
103	THU0432â€Bone erosions in rheumatoid arthritis: Ultrasound findings in the early stage of the disease. Annals of the Rheumatic Diseases, 2013, 71, 301.2-301.	0.9	4
104	A Case of Recalcitrant Psoriatic Arthritis to TNF Inhibitors Improved After Administration of Secukinumab, an IL-17A Inhibitor. Rheumatology and Therapy, 2017, 4, 509-513.	2.3	4
105	Comment on: Assessments of the unmet need in the management of patients with rheumatoid arthritis: analyses from the NOR-DMARD registry. Rheumatology, 2019, 58, 1883-1884.	1.9	4
106	Calcified constrictive pericarditis resulting in tamponade in a patient with systemic lupus erythematosus. Rheumatology International, 2021, 41, 651-670.	3.0	4
107	Role of Hepcidin in Anemia of Chronic Disease in Rheumatoid Arthritis. Journal of Laboratory Physicians, 2021, 13, 317-322.	1.1	4
108	A Patient with Symmetrical Polyarthritis. The Value of Conventional Radiography for a Correct Diagnosis. Rheumatology and Therapy, 2022, 9, 771-779.	2.3	4

#	Article	IF	Citations
109	Early rheumatoid arthritis: does gender influence disease expression?. Clinical and Experimental Rheumatology, 2004, 22, 165-70.	0.8	4
110	Persistent Clinical Response of Infliximab Therapy in Patients with Refractory Rheumatoid Arthritis, over a 3-Year Period. Current Clinical Pharmacology, 2006, 1, 103-108.	0.6	3
111	Long-term use of adalimumab in the treatment of rheumatic diseases. Open Access Rheumatology: Research and Reviews, 2009, 1, 51.	1.6	3
112	An Extensive Study of the Functional Polymorphisms of Kinin-Kallikrein System in Rheumatoid Arthritis Susceptibility. Archives of Rheumatology, 2018, 33, 33-38.	0.9	3
113	Occupational mimics of rheumatoid arthritis: hair dye-induced arthritis. Rheumatology International, 2021, 41, 795-797.	3.0	3
114	Opportunistic screening for hypertension: what does it say about the true epidemiology?. Journal of Human Hypertension, 2022, 36, 364-369.	2.2	3
115	D-penicillamine in early rheumatoid arthritis. Clinical and Experimental Rheumatology, 1997, 15, 580-1.	0.8	3
116	Thyroid dysfunction in Greece: Results from the national health examination survey EMENO. PLoS ONE, 2022, 17, e0264388.	2.5	3
117	Adiponectin, leptin and resistin levels in first-episode, drug-na \tilde{A} -ve patients with psychosis before and after short-term antipsychotic treatment. Journal of Psychosomatic Research, 2022, 157, 110789.	2.6	3
118	TNFα inhibitor biosimilars associated with alopecia areata. Case-based review. Rheumatology International, 2022, 42, 1113-1117.	3.0	3
119	Treatment strategies of Covid-19. A rheumatology perspective European Journal of Internal Medicine, 2022, , .	2.2	3
120	Subcutaneous lesions in dermatomyositis. Rheumatology, 2006, 45, 165-165.	1.9	2
121	Avascular necrosis in a patient with systemic lupus erythematosus. Joint Bone Spine, 2013, 80, 665.	1.6	2
122	Joint complaints correlate with increased serum IgE levels in patients hospitalized for moderate-to-severe psoriasis: A single center retrospective study. Journal of the American Academy of Dermatology, 2016, 74, 1014-1015.e4.	1.2	2
123	Evidence of <i><scp>ERBB</scp>3</i> gene association with rheumatoid arthritis predisposition. International Journal of Rheumatic Diseases, 2016, 19, 146-149.	1.9	2
124	Insulin resistance in patients with rheumatoid arthritis. Rheumatology International, 2021, 41, 1185-1186.	3.0	2
125	Pleural effusion in psoriatic arthritis patients: a case series and review of the literature. Clinical Rheumatology, 2021, 40, 4741-4748.	2.2	2
126	Current Therapeutic Options for the Treatment of Juvenile Idiopathic Arthritis. Current Rheumatology Reviews, 2021, 17, 41-57.	0.8	2

#	Article	IF	CITATIONS
127	Five-year prospective multi-center cohort study of patients with giant cell arteritis in Greece. Mediterranean Journal of Rheumatology, 2018, 29, 103-105.	0.8	2
128	Orbital myositis in systemic lupus erythematosus: a case-based review. Rheumatology International, 2022, 42, 1453-1460.	3.0	2
129	The effects of biologic agents on cardiovascular risk factors and atherosclerosis in rheumatoid arthritis patients: a prospective observational study. Heart and Vessels, 2022, 37, 2128-2136.	1.2	2
130	A7.19â€Positive Association of TAGAP Rs212389 Polymorphism with Rheumatoid Arthritis Susceptibility. Annals of the Rheumatic Diseases, 2013, 72, A54.3-A55.	0.9	1
131	Reply to the comment "Effect of Infliximab on Male Fertility―by Younis et al Joint Bone Spine, 2014, 81, 103.	1.6	1
132	Unmet needs in the treatment of ankylosing spondylitis: a long-term observational study from a single university center. Rheumatology International, 2019, 39, 663-668.	3.0	1
133	Correspondence on ‴Cardiovascular effects of biological versus csDMARD therapy in treatment naive, early rheumatoid arthritis'. Annals of the Rheumatic Diseases, 2023, 82, e89-e89.	0.9	1
134	Methotrexate and interstitial lung disease. Is there a real causative factor?. Rheumatology International, 2021, 41, 2045-2046.	3.0	1
135	Single photon emission computed tomography myocardial perfusion imaging in patients with moderate to severe psoriosissis. Nuclear Medicine Review, 2021, 24, 46-50.	0.5	1
136	Fibroblastic rheumatism: an uncommon arthritis. A case-based review. Rheumatology International, 2022, 42, 1097-1103.	3.0	1
137	Clinical, Serological and Immunological Characteristics in Greek Patients with Psoriatic Arthritis: The Role of IL-17, IL-23, and Sclerostin. Mediterranean Journal of Rheumatology, 2020, 31, 235.	0.8	1
138	A not-to-miss Cause of Severe Cervical Spine Pain in a Patient with Rheumatoid Arthritis: A Case-Based Review. Mediterranean Journal of Rheumatology, 2021, 32, 256.	0.8	1
139	Transfusion-related acute lung injury in a patient with systemic lupus erythematosus. Clinical and Experimental Rheumatology, 2017, 35, 353.	0.8	1
140	Epidemiological characteristics of psoriatic arthritis. Clinical and Experimental Rheumatology, 2019, 37, 324-332.	0.8	1
141	A7.13 IRAK1 Rs3027898 Polymorphism: A Variant Implicated in the Pathogenesis of more than one Inflammatory Disease. Annals of the Rheumatic Diseases, 2013, 72, A52.2-A52.	0.9	0
142	A7.12 Identification of the Semaphorin Receptor Plexin-A2 as a Candidate Gene for Susceptibility to Ankylosing Spondylitis. Annals of the Rheumatic Diseases, 2013, 72, A52.1-A52.	0.9	0
143	AB0012â€Positive association of tagap rs212389 polymorphism with rheumatoid arthritis susceptibility. Annals of the Rheumatic Diseases, 2013, 72, A789.3-A789.	0.9	0
144	AB0924â€Psychological distress symptoms and illness perceptions associated with health-related quality of life in psoriatic arthritis patients. Annals of the Rheumatic Diseases, 2013, 71, 691.12-691.	0.9	0

#	Article	IF	Citations
145	A7.22â€The ETS1 Transcription Factor May Predispose to Rheumatoid Arthritis Susceptibility. Annals of the Rheumatic Diseases, 2013, 72, A55.3-A56.	0.9	O
146	AB0013â€First report of erbb3 gene association with rheumatoid arthritis predisposition. Annals of the Rheumatic Diseases, 2013, 72, A789.4-A789.	0.9	0
147	FRI0179 Infliximab infusion reactions in patients with rheumatoid arthritis and spondylarthropathies. Annals of the Rheumatic Diseases, 2013, 72, A432.2-A432.	0.9	O
148	AB0123â€Antibodies to Porphyromonas Gingivalis in Patients with Rheumatoid Arthritis. Annals of the Rheumatic Diseases, 2014, 73, 844.3-844.	0.9	0
149	FRIO415â€Patients' Illness Perceptions Are Associated with Physical Health-Related Quality of Life Independent of Psychological Distress and Disease Severity in Primary Sjogren's Syndrome, Systemic Lupus Erythematosus and Rheumatoid Arthritis. Annals of the Rheumatic Diseases, 2014, 73, 537.3-537.	0.9	0
150	AB0743â€Prevalence of the Metabolic Syndrome According to Various Definitions in Patients with Psoriatic Arthritis. Annals of the Rheumatic Diseases, 2014, 73, 1049.2-1049.	0.9	0
151	AB0683â€Prevalence of the Metabolic Syndrome According to Various Definitions in Patients with Ankylosing Spondylitis. Annals of the Rheumatic Diseases, 2014, 73, 1031.1-1031.	0.9	0
152	THU0130â€Mental Illness, Suicidality Risk and Associated Illness Perceptions in People with Chronic Inflammatory Rheumatic Diseases Seeking Urgent Care in the Emergency Department. Annals of the Rheumatic Diseases, 2015, 74, 241.1-241.	0.9	0
153	SAT0234â€Counting Costs Under Severe Financial Constraints: A Cost of Illness Analysis of Spondyloarthropathies in Greece. Annals of the Rheumatic Diseases, 2015, 74, 743.2-743.	0.9	0
154	SAT0382â€Therapeutic Response in Psoriatic Arthritis Patients Receiving Biological or Conventional Disease Modifying Antirheumatic Drugs. A 5-Year Observational Study. Annals of the Rheumatic Diseases, 2016, 75, 806.2-806.	0.9	0
155	AB0476 Inner ear involvement in systemic rheumatic diseases. , 2017, , .		O
156	Image Gallery: Capillaroscopy for noninvasive scabies diagnosis. British Journal of Dermatology, 2018, 179, e133-e133.	1.5	0
157	THU0671â€PULMONARY INVOLVEMENT IN RHEUMATOID ARTHRITIS: PATTERNS AND EPIDEMIOLOGICAL CHARACTERISTICS FROM A MONOCENTRIC COHORT STUDY. , 2019, , .		0
158	AB1272â€TREATMENT OF RHEUMATOID ARTHRITIS WITH EXTENSION OF THE ANTI-TNF INTERDOSE INTERVALS. MONOCENTRIC OFF-LABEL STUDY. , 2019, , .	. A	0
159	AB0678â€ANTIPROLIFERATIVE AND VASOACTIVE TREATMENT MODALITIES IN 457 CONSECUTIVE PATIENTS WIT SYSTEMIC SCLEROSIS FROM ACADEMIC CENTERS IN GREECE. , 2019, , .	TH	0
160	SAT0247â€FEMALE SEX AND AGE AT DIAGNOSIS ARE ASSOCIATED WITH A DECREASED POSSIBILITY OF DRUG DISCONTINUATION IN GIANT CELL ARTERITIS: DATA FROM A MULTICENTER PROSPECTIVE COHORT OF 177 PATIENTS. , 2019, , .		O
161	Reply to the Editor. Seminars in Arthritis and Rheumatism, 2020, 50, e7.	3.4	O
162	Aeromonas hydrophila Survives the Treatment of Posttraumatic Cellulitis in the Shelter of an Obscured Fish-Bone Fragment. Case Reports in Dermatological Medicine, 2020, 2020, 1-3.	0.3	0

#	Article	IF	CITATIONS
163	FRI0245â€Clinical course and outcome in mixed connective tissue disease. , 2001, , .		O
164	AB0720â€Systemic sclerosis and cancer development. a single-centre experience. , 2018, , .		0
165	FRI0101â€Unmet needs in the treatment of rheumatoid arthritis. an observational study and a real-life experience from a single university centre. , 2018, , .		O
166	FRIO493â€THE INTERLEUKIN-1B INHIBITOR CANAKINUMAB FOR REFRACTORY STILL'S DISEASE: LONG-TERM EXPERIENCE IN 50 CONSECUTIVE PATIENTS. Annals of the Rheumatic Diseases, 2020, 79, 845.1-845.	0.9	0
167	Rheumatoid resorptive arthropathy. Clinical and Experimental Rheumatology, 1999, 17, 474-6.	0.8	O
168	Catastrophic rheumatoid arthritis. Journal of Rheumatology, 2008, 35, 2062-3.	2.0	0
169	Uncommon presentation of granulomatosis with polyangiitis in association with subclinical coeliac disease. Clinical and Experimental Rheumatology, 2018, 36 Suppl 111, 160.	0.8	0
170	Combined seronegativity in Sj \tilde{A} ¶gren's syndrome. Clinical and Experimental Rheumatology, 2021, , .	0.8	0
171	Hyperlipidemia and rheumatoid arthritis., 2022,, 969-997.		0
172	A Response to: Letter to the Editor Regarding the Article: "Colchicine Against SARS-CoV-2 Infection: What is the Evidence?― Rheumatology and Therapy, 0, , .	2.3	0